UPDATE | November 17, 2025

End-to-end saRNA manufacturing: Integrated development and in vivo potency

  • MAIL

End to end saRNA manufacturing Integrated development and in vivo potency


A self-amplifying RNA (saRNA) platform that is not only integrated from in vitro  transcription (IVT) optimization to LNP formulation, but also scalable, cost-efficient, and GMP-compliant? 


Samsung Biologics has developed a strategic, two-pronged workflow: 


  • an saRNA IVT platform that maximizes titer and integrity in a cost-efficient, GMP-aligned manner, and 
  • an LNP formulation platform that delivers mRNA/saRNA tailored to client-specific performance and targeting requirements.

End to end saRNA manufacturing Integrated development and in vivo potency


A self-amplifying RNA (saRNA) platform that is not only integrated from in vitro  transcription (IVT) optimization to LNP formulation, but also scalable, cost-efficient, and GMP-compliant? 


Samsung Biologics has developed a strategic, two-pronged workflow: 


- an saRNA IVT platform that maximizes titer and integrity in a cost-efficient, GMP-aligned manner, and 

an LNP formulation platform that delivers mRNA/saRNA tailored to client-specific performance and targeting requirements.

Share article

Related Content

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required